This article was written by

Many people believe that starting a business always requires money. While having capital can certainly help, it is not always necessary. In reality, there are many ways to start earning income using only your time, skills, and creativity.

If you are currently struggling financially and need to earn money immediately—even within the same day—there are several simple business ideas you can start right away without spending anything.

The key is to focus on services instead of products. Services rely on effort rather than capital, which means you can start immediately using what you already have.

Here are nine practical business ideas you can try today if you need to earn money quickly without any upfront investment.

1. Offer Errand Services

Many people are simply too busy to complete everyday tasks. This creates an opportunity for you to earn money by offering errand services.

You can help people with tasks such as:

• Buying groceries
• Picking up packages
• Paying bills
• Dropping off documents
• Waiting in line for services

Start by offering your service to neighbors, coworkers, or friends through social media. Even charging a small service fee can quickly add up if you complete multiple errands in a day.

Since this only requires your time and willingness to help, it is one of the easiest ways to earn money immediately.

2. Sell Unused Items Online

One of the fastest ways to earn money within the day is by selling items you already own but no longer use.

Look around your home and identify things such as:

• Clothes you rarely wear
• Old gadgets or accessories
• Books
• Kitchen tools
• Unused decorations

Take clear photos and post them on Facebook Marketplace, community groups, or messaging apps. Price them slightly lower than market value to attract buyers quickly.

Many people manage to sell items within hours, especially if the price is reasonable.

3. Offer Cleaning Services

Cleaning services are always in demand. Many homeowners would gladly pay someone to help clean their house, yard, or garage.

You can offer services such as:

• Basic house cleaning
• Garage organizing
• Yard sweeping
• Dishwashing
• Laundry assistance

Start by posting in local Facebook groups or messaging neighbors. Since this type of service requires effort rather than capital, it is perfect for earning money quickly.

Even a single cleaning job can bring immediate income on the same day.

4. Become a Local Delivery Helper

With the rise of online selling and food deliveries, many small sellers need help delivering items to customers.

If you have a bicycle, motorcycle, or even just the ability to walk short distances, you can offer delivery services for local sellers.

Message online sellers in your area and offer to deliver their orders for a small fee. Some sellers are happy to outsource deliveries because it saves them time and effort.

This can quickly turn into multiple delivery tasks in one day.

5. Offer Basic Tech Help

Not everyone is comfortable with technology. Many people need help with simple tasks like setting up apps, installing software, or fixing small phone or computer issues.

If you have basic tech knowledge, you can offer help such as:

• Installing applications
• Setting up email accounts
• Cleaning phone storage
• Troubleshooting slow devices
• Teaching basic smartphone usage

Even simple tech assistance can be valuable to those who struggle with digital devices.

You can charge a small service fee and finish multiple tasks within the same day.

6. Offer Writing or Typing Services

If you have access to a computer or smartphone and can type quickly, you can offer writing or typing services.

Examples include:

• Typing handwritten notes
• Creating simple documents
• Transcribing audio recordings
• Writing short social media captions

Students, small businesses, and content creators often need quick help with these tasks.

Promote your service on social media or among friends who might need assistance.

7. Pet Sitting or Dog Walking

Pet owners sometimes need someone to watch or walk their pets while they are busy or away from home.

You can offer services such as:

• Dog walking
• Pet feeding
• Short-term pet sitting
• Cleaning pet areas

This can be a fun and easy way to earn money while spending time with animals.

Ask neighbors or post in community groups to find pet owners who need help.

8. Offer Simple Tutoring

If you are good at a particular subject, you can offer tutoring services to students who need help.

This could include:

• Basic math tutoring
• English conversation practice
• Homework assistance
• Exam preparation

You do not need to be a professional teacher. Many parents simply want someone patient who can help their children understand lessons better.

Even short tutoring sessions can provide immediate income.

9. Social Media Posting for Small Businesses

Many small businesses want to promote their products online but do not have the time to manage their social media pages.

You can offer simple services such as:

• Posting product photos
• Writing captions
• Replying to basic messages
• Sharing posts in groups

If you already spend time on social media, this can easily become a small service business.

Start by contacting small online sellers and offering affordable help managing their posts.

When money is tight, the most important thing is to focus on action instead of waiting for the perfect opportunity. Many successful entrepreneurs started with nothing but determination and a willingness to work.

The good news is that earning money does not always require large investments. By offering useful services, helping others solve small problems, and using the skills you already have, it is possible to start earning income immediately.

Try one or two of these ideas today and see which works best for you. Sometimes, the simplest opportunities can lead to bigger business ideas in the future.

Remember, every successful business once started with a single small step.

The startup ecosystem around the Indian Institute of Technology (IIT) Bombay is increasingly translating into wealth creation as companies incubated or supported by the institute’s entrepreneurship arm head toward the public markets.

Through its incubator, the Society for Innovation and Entrepreneurship (SINE), IIT Bombay has already seen significant gains from startup listings such as ideaForge and is now poised for another windfall from the IPO of Sedemac Mechatronics.

With companies like Atomberg Technologies and Gupshup also exploring public listings, the institute’s long association with technology startups is beginning to deliver substantial financial returns.

ideaForge: Early success story

One of the earliest examples of this success is ideaForge Technology, India’s leading drone manufacturer. The company was founded in 2006 by IIT Bombay alumni Ankit Mehta, Rahul Singh and Ashish Bhat and was incubated at SINE during its formative years.

ideaForge launched its IPO in July 2023 and the issue drew massive investor interest, being subscribed about 106 times. The stock listed at a strong premium, briefly doubling shareholder wealth on its debut.
For SINE, the listing translated into a meaningful monetisation opportunity. The incubator held roughly 1 lakh shares in the company prior to the IPO. At the upper end of the IPO price band of Rs 672 per share, the value of that stake was estimated at around Rs 6-7 crore.
SINE partially exited during the offer for sale, selling about 22,600 shares and realising roughly Rs 1.52 crore from the transaction, while continuing to retain a stake in the company.

Sedemac: A much larger windfall

The institute is now set to benefit even more from the IPO of Sedemac Mechatronics, another startup that emerged from the IIT Bombay ecosystem.

Sedemac was founded in 2007 by Shashikanth Suryanarayanan, an associate professor in the institute’s mechanical engineering department, along with other early team members who were students or researchers associated with the campus.

The company has grown into a manufacturer of electronic control units and genset controllers used across two-wheelers, electric vehicles and industrial applications.

SINE backed the company in its early stages and currently holds 4.08 lakh shares, representing about 0.92% stake.

At the upper end of the IPO price band of Rs 1,352 per share, the value of SINE’s holding stands at roughly Rs 55 crore.

As part of the offer for sale, the incubator plans to sell 2.04 lakh shares. At the IPO price, this portion alone would fetch around Rs 27.58 crore.

The scale of the return is remarkable given the acquisition price. SINE acquired the shares at an average cost of Rs 0.01 each, meaning the 2.04 lakh shares being sold cost only about Rs 2,040.

At the IPO price, the sale implies a gain of about Rs 27.58 crore and a return of roughly 1.3 lakh times the original investment. Even after the partial exit, SINE will continue to hold another 2.04 lakh shares in the company, leaving it with a residual stake worth roughly Rs 27-28 crore at the IPO price.

More IPO candidates emerging

The IIT Bombay startup ecosystem could see more companies head to the stock market in the coming years.

Consumer appliances company Atomberg Technologies is among the startups exploring a public listing. The Temasek-backed firm is weighing an IPO in Mumbai that could raise around $200 million, according to Bloomberg.

Founded in 2012 by IIT Bombay alumni Manoj Meena and Sibabrata Das, Atomberg began by manufacturing energy-efficient ceiling fans and has since expanded into products such as mixer grinders, water purifiers and smart locks.

The company has attracted several prominent investors over the years. In 2023 it raised $86 million in funding from Temasek, Steadview Capital, Jungle Ventures and Inflexor Ventures.

Another startup with links to IIT Bombay’s incubation ecosystem is Gupshup, a conversational messaging platform founded by Beerud Sheth.

The company received early incubation support from SINE during its formative years and has since grown into one of the world’s largest messaging platforms for businesses.

Gupshup recently raised $60 million in fresh funding from Globespan Capital Partners along with debt financing from EvolutionX Debt Capital. The San Francisco-headquartered firm is also considering shifting its domicile to India ahead of a potential public listing in the country within the next one to two years.

Founded in 2004, Gupshup processes more than 120 billion messages annually for over 50,000 businesses across 130 countries.

From campus labs to public markets

For IIT Bombay, the growing list of IPO-bound startups highlights how academic incubation programs are increasingly shaping India’s startup economy. Through SINE, the institute has supported hundreds of early-stage ventures over the past two decades. While many remain private, a handful are now reaching a stage where they can tap public markets.

As companies like Sedemac, Atomberg and potentially Gupshup move closer to listing, IIT Bombay’s long-running experiment with technology incubation is beginning to translate into tangible financial returns alongside entrepreneurial success.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

SAN CARLOS, Calif. — Shares of **Iovance Biotherapeutics Inc.** (NASDAQ: IOVA) climbed sharply in early March 2026 trading, fueled by renewed analyst optimism and ongoing commercial progress for its flagship tumor-infiltrating lymphocyte (TIL) therapy, **Amtagvi** (lifileucel). The biotech company’s stock, which has hovered in the low single digits for much of the year, gained traction after multiple price target increases and positive commentary on its revenue trajectory.

As of March 7, 2026, IOVA closed at approximately $5.13, up from recent lows around $4.58, with intraday highs reaching $5.16 in heavy volume sessions. The stock has seen notable volatility, trading in a 52-week range from $1.64 to $5.16, reflecting broader biotech sector pressures but also bursts of enthusiasm tied to clinical and commercial milestones.

The latest catalyst came from UBS, which raised its price target on IOVA from $2 to $4, citing strong fourth-quarter revenue growth for Amtagvi despite a challenging market environment. Other firms followed suit: Baird increased its target to $4 from $3, Barclays to $11 from $10, and Citizens upgraded the stock to Outperform from Market Perform. These adjustments highlight growing confidence in Iovance’s ability to scale its pioneering TIL platform beyond advanced melanoma.

Amtagvi, the first FDA-approved TIL therapy, received accelerated approval in February 2024 for adult patients with unresectable or metastatic melanoma previously treated with other therapies. The personalized cell therapy, manufactured from a patient’s own tumor tissue, has driven rapid revenue ramp-up in its first full commercial year.

Iovance reported preliminary full-year 2025 product revenue of approximately $264 million, within its guided range of $250 million to $300 million. This marked a 61% increase from 2024’s $164.1 million, largely propelled by Amtagvi’s U.S. sales of about $220 million and global Proleukin (aldesleukin) contributions of roughly $44 million. Fourth-quarter product revenue hit $86.8 million, up about 30% sequentially, with gross margins improving to around 50% as manufacturing efficiencies took hold.

Management emphasized accelerating demand through an expanding network of authorized treatment centers (ATCs), faster production turnaround times (32 days or less), and supportive real-world data demonstrating durable responses in advanced melanoma. In a February 2026 earnings update, executives described 2026 as poised for “remarkable” revenue growth, with detailed U.S. product guidance forthcoming soon. Long-term goals include gross margins approaching 70% through full internalization of lifileucel manufacturing.

Pipeline advancements further bolster the bullish case. On February 24, 2026, Iovance announced positive early results from the first clinical trial of lifileucel in soft tissue sarcomas, specifically undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). The study showed a 50% confirmed objective response rate, prompting plans for a registrational trial. The data, presented at scientific meetings, sparked a 25%+ single-day stock surge earlier in the year.

In non-small cell lung cancer (NSCLC), lifileucel earned FDA Fast Track designation for second-line advanced non-squamous NSCLC, supported by interim data showing a 26% objective response rate and durable benefit compared to standard docetaxel. Management targets a supplemental biologics license application (sBLA) and potential accelerated approval/launch in the second half of 2027, eyeing a multibillion-dollar U.S. peak sales opportunity in lung cancer—potentially seven times larger than melanoma.

Additional trials explore frontline melanoma combinations (TILVANCE-301), second-line NSCLC (IOV-LUN-202), endometrial cancer (IOV-END-201), and next-generation engineered TIL therapies like IOV-5001, with an IND submission planned for the first half of 2026. International regulatory progress includes priority reviews in Australia and recommendations in Switzerland, with decisions expected in early 2026.

Financially, Iovance ended 2025 with about $303 million in cash, providing runway into the third quarter of 2027. Full-year costs and expenses totaled around $667 million, resulting in a net loss of $391 million, or $1.09 per share—improvements over prior periods but underscoring the cash-intensive nature of commercial-scale cell therapy.

Analysts maintain a mixed but increasingly positive consensus, with average price targets around $9–$10 implying substantial upside from current levels. High-risk elements persist: competition in solid tumors, manufacturing complexities, and the need for consistent revenue scaling amid biotech funding challenges. Yet, Iovance’s leadership in TIL therapy positions it as a potential platform player if label expansions materialize.

Upcoming investor visibility includes presentations at the TD Cowen 46th Annual Healthcare Conference on March 2 and the Barclays 28th Annual Global Healthcare Conference on March 11, where leadership will likely discuss growth drivers and 2026 guidance.

As Iovance transitions from launch-year execution to multi-indication expansion, the stock’s performance hinges on Amtagvi’s sustained momentum and pipeline catalysts. Investors watch closely for first-quarter 2026 results, expected in May, which could provide clearer visibility into the year’s trajectory.

With its innovative approach to solid tumor immunotherapy and accelerating commercial story, Iovance Biotherapeutics remains a high-conviction name in the biotech space amid 2026’s evolving oncology landscape.